Blog
Read our latest blog entries and find out what Nordic Bioscience is up to.
Have you considered that biomarkers are different? Biomarkers aren't just confined to different omics categories; various classes are referring to the types of serological measurements.
We have put together some our best publications that we and our collaborators worked on in the second quarter of 2023—in no particular order. We invite you to browse and read according to your interests!
Nordic Bioscience's ECM-based dermatology biomarkers offer a unique approach that sets them apart from competitors, providing deeper insights into tissue formation, degradation, and resolution processes related to skin diseases.
In the field of clinical trials, accuracy and reliability are critical to success. For this reason, Nordic Bioscience Laboratory is dedicated to providing the highest quality laboratory services, with a strong focus on data integrity, customer satisfaction, and scientific excellence.
Collagen is a crucial protein that provides structural support and strength to tissues throughout the body. However, there is a group of highly specialized minor collagens that may play a critical role in cancer progression.
Animal testing is required by the FDA for all premature drugs in development. Therefore, planning the transition from preclinical to clinical is critical to success. But how do we know if the same pathology in humans is reflected in rodent biology? Quite simply, we do not!
Conventional serum calprotectin biomarkers are often not as clinically useful as the fecal versions because of the half-life of calprotectin in blood (only 5-6 hours), which leads to dissociation of the calprotectin protein.
Nordic Bioscience developed a novel, blood-based calprotectin biomarker assay that demonstrably quantifies collagen remodeling in Chron's Disease and other diseases.
NASH is often characterized by multiple organ failure, with hepatic cirrhosis driving organ decompensation. But how do we know which organ decompensates first?
We need to talk about the good and the bad fibroblasts.
We believe it is time to put kidney fibrosis more in the center - even in diseases where other aspects (such as kidney volume) are the focus of attention.
We have examined the effect of copper depletion therapy on the collagen microenvironment in breast cancer patients with high risk of relapse.
If we are to develop precision medicine, we need to identify the right patients. Using Big Data is critical in clinical research, but there is a catch.
Despite its pivotal role, the mechanical load is rarely a component of translational drug screening assays when testing novel osteoarthritis treatments. We want to change that!
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
